Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 93N4J | — |
Shingrix dose 3 on 6/6/25; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 65-year-old female patient who received Herpes zoster (Shingrix) (batch number 93N4J) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 11-FEB-2021 with batch number 3K743) and Shingrix (received 2nd dose on 18-AUG-2021 with batch number PG35Z). On 06-JUN-2025, the patient received the 3rd dose of Shingrix. On 06-JUN-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Shingrix dose 3 on 6/6/25). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 09-JUN-2025 The health care professional reported that a female patient who was given 3rd vaccination of Shingrix and they did not need it, which led to extra dose administered. The vaccine administration facility was the same as primary reporter.